Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET
Company Participants
Erick Lucera – Chief Financial Officer
Conference Call Participants
Dae Gon Ha – Stifel
Dae Gon Ha
All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we’ve got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. So thanks, guys, for coming and joining us.
Let’s briefly start with what Editas is all about, the CRISPR approach that you guys are using, the programs that you have, and then we’ll dive into Q&A.
Erick Lucera
Yeah, sure. So for those of you that haven’t met us or met me, my name is Erick Lucera, I’m the CFO. And I’ve been at Editas for about a year and a half. Before that, I was at a couple of other biotech companies. And before that, spent 15 years on the buy side as an investor. And I was always attracted to the technology of gene editing and the ability to generate a cure with maybe one treatment or one shot.
And what Editas has been focused on is really what we call our 3-pillar strategy, which was refined about 2 years ago when Gilmore O’Neill came in from Sarepta and kind of tried to begin the transition of Editas into an in vivo company. So with that, he set up the 3 pillars of kind of who we are.
The first is reni-cel, which is our only autologous treatment. It’s for sickle cell. We recently announced that we would seek a partner for that. We believe it has potential best-in-class efficacy. But where our focus in for the
Read the full article here